Galmed Pharmaceuticals Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GLMD Nasdaq 2830 galmedpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition - Jun 22nd, 2026 5:00 am
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - Jun 8th, 2026 5:00 am
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - Jun 2nd, 2026 5:30 am
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - May 14th, 2026 5:30 am
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - May 6th, 2026 5:30 am
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - Apr 14th, 2026 5:30 am
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - Apr 9th, 2026 5:30 am
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - Mar 31st, 2026 2:15 pm
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - Jan 30th, 2026 2:15 pm
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - Dec 8th, 2025 6:30 am
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - Dec 4th, 2025 6:30 am
Galmed Issues CEO Letter to Shareholders - Dec 1st, 2025 6:30 am
Galmed Pharmaceuticals: Q3 Earnings Snapshot - Nov 26th, 2025 6:56 am
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 26th, 2025 6:30 am
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine - Nov 18th, 2025 6:30 am
BC-Most Active Stocks - Nov 17th, 2025 8:30 am
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - Nov 17th, 2025 6:30 am
Galmed Pharmaceuticals: Q2 Earnings Snapshot - Aug 28th, 2025 6:08 am
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 28th, 2025 6:00 am
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value - Aug 25th, 2025 5:30 am